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Abstract: Chronic heart failure (CHF) is common, and increases in incidence and prevalence 
with age. There are compelling data demonstrating reduced mortality and hospitalizations with 
adrenergic blockade in older patients with CHF. Despite this, many older patients remain under-
treated. The aim of the present article is to review the potential mechanisms of the beneﬁ  ts of 
adrenergic blockade in CHF and the clinical data available from the large randomized studies, 
focusing particularly on older patients.
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Introduction
Chronic heart failure (CHF) is common. It affects 2% of people between 50 and 60 years 
of age (Dargie et al 1992), yet the prevalence increases to approximately 10% of those 
over 80 years (Cowie et al 1997). The incidence of CHF is rising (Bonneux et al 1994; 
Brown and Cleland 1998) at the same rate in men as women, although men present 
at an earlier age (Cowie et al 1999). CHF has a high mortality (30% at one year, and 
60%–70% after 5 years), [2] and is one of the leading causes of death in industrialized 
countries (Braunwald 1997). Patients with CHF also have a high morbidity. Of all 
UK medical hospital admissions, 5% (120,000 per year (Sutton 1990; McMurray and 
Dargie 1992)) are due to heart failure, making it the single most common reason for 
medical admission (Brown and Cleland 1998) and costing around £360 million per 
year (McMurray et al 1993a). New medical and device treatments have had beneﬁ  ts on 
symptoms and prognosis (Cleland, Swedberg et al 1998), but high readmission rates 
(20% of patients needing two or more admissions per year (McMurray et al 1993b) for 
heart failure and other reasons, including chest pain, arrhythmias and stroke (Brown 
and Cleland 1998; Cleland et al 2001; Khand et al 2001), and reduced quality of life 
(Stewart et al 1989) remain features of CHF.
Figure 1a shows the distribution of age in a large community based heart failure 
clinic in the North of England. Most patients with chronic heart failure are over 70 years 
of age. Similarly, patients admitted with decompensated heart failure are also most 
likely to be aged between 70 and 79 years (Figure 1b) (Nieminen et al 2006). Mortal-
ity and morbidity in chronic heart failure are directly related to age (Cleland, Massie 
et al 1999; Dulin et al 2005) with older patients less likely to survive an admission 
with heart failure than younger individuals (Cleland, Massie, et al 1999), and much 
more likely to be readmitted in the subsequent 6 months, requiring more bed days 
(Cleland and Clark 1999). Few randomized studies have examined the effects of treat-
ment speciﬁ  cally in older ( 65 years) patients. The mean age of the populations in 
almost all randomized studies of patients with chronic heart failure is around 60 years 
(Table 1). However, in those trials with published sub-studies, or where the outcomes 
have been examined by age group, the relative reduction in mortality in older patients 
is generally similar to that seen in younger subjects, and as a consequence of their Clinical Interventions in Aging 2008:3(1) 56
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poorer absolute outcome, the number needed to treat to 
extend life or prevent hospital admission is much lower in 
older patients.
Despite these facts, elderly patients with chronic heart fail-
ure are frequently under-treated with disease-modifying drugs 
(Komadja et al 2003). They are less likely to be prescribed an 
angiotensin converting enzyme inhibitor or a β-blocker (Sin 
and McAlister 2002; Maggioni et al 2003), and have uptitra-
tion of these agents to the recommended doses less frequently 
(Komadja et al 2003). The aim of the present article is to review 
the data for disease modifying drugs in elderly patients with 
CHF focusing on the effects and mechanisms of action of the 
adrenoceptor antagonists, speciﬁ  cally carvedilol.
Non-adrenergic blockade therapy 
for chronic heart failure
Angiotensin converting enzyme (ACE) 
inhibitors
ACE inhibitors block the degradation of bradykinin and the 
formation of angiotensin II, the product of the heightened 
renin-angiotensin system activity due to heart failure and the 
diuretics used to treat it. This blockade results in venous and 
arterial dilatation, a fall in arterial pressure and an increase 
in renal blood ﬂ  ow. ACE inhibitors improve symptoms 
and retard the progression of ventricular dysfunction and 
consequently worsening of symptoms (The SOLVD Inves-
tigators 1991; Yusuf, Nicklas et al 1992; Yusuf et al 2000; 
Jong et al 2003) Treatment of patients with asymptomatic 
left ventricular dysfunction, either chronic (Yusuf, Nicklas 
et al 1992) or occurring soon after a myocardial infarction 
(Pfeffer et al 1992; Ball et al 1993; Flather et al 2000), delays 
the development of heart failure and reduces mortality (The 
CONSENSUS Trial Study Group 1987; Cohn et al 1991; 
Cleland, Freemantle et al 1999), reduces total hospitalizations 
(Yusuf, Pepine et al 1992; Garg and Yusuf 1995; Packer et al 
1999; Torp-Pedersen and Kober 1999), days in hospital (The 
Solvd investigators 1991; Jong et al 2003), and increases 
average life expectancy by 6–36 months (The SOLVD 
investigators 1991; Swedberg et al 1999; Cleland et al 2001). 
Higher doses appear more effective in reducing morbidity 
(The NETWORK Investigators 1998; Packer et al 1999).
Overall there seems to be no difference in beneﬁ  t between 
older and younger patients in any of the outcomes from ACEi 
in patients with systolic dysfunction (Garg and Yusuf 1995). 
The ﬁ  rst trial into the effect of ACE inhibitors enrolled 253 
patients with a mean age of 70 years (range 36–91). Enalapril 
2.5–40 mg per day lead to a 40% reduction in mortality due 
to progressive heart failure over placebo. The only other 
ACE inhibitor trial performed in older ( 70 years) patients 
examined outcomes in patients with chronic heart failure with 
preserved left ventricular systolic function revealing reduc-
tions in hospitalisations and improvements in symptoms, 
along with a trend to reduced total mortality after one year 
(Cleland, Tendera, et al 2006).
Aldosterone antagonists
Aldosterone, increased in CHF due to renin-angiotensin 
system activation and impaired liver function, leads to 
Figure 1 (a) Age distribution of 3924 consecutive patients admitted to hospital 
as an emergency with a diagnosis of heart failure between 2003 and 2005. (b) Age 
distribution of 2002 consecutive patients being followed up for a diagnosis of heart 
failure due to left ventricular systolic dysfunction in a community heart failure clinic.
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potassium wasting and stimulates myocardial and vascular 
collagen synthesis. ACE inhibitors do not block all aldoste-
rone production; other enzymes, such as chymase, convert 
angiotensin I to angiotensin II with resultant aldosterone 
production – known as aldosterone ‘escape’ (Pitt 1995). 
Adding aldosterone antagonists to ACE inhibitors reduces 
noradrenaline levels, collagen turnover and ventricular 
arrhythmias on Holter monitoring and increases heart rate 
variability (Barr et al 1995; MacFadyen et al 1997). In 
the post-infarction setting (Pitt et al 2003), aldosterone 
antagonists reduce hospital admissions with heart failure 
and mortality, predominantly sudden death, indicating that 
they may have a role for the management of asymptomatic 
patients. Aldosterone antagonists seem most effective when 
added on top of ACE inhibitors and beta-blockers (Pitt et al 
1999, 2003). There are no data to indicate whether beneﬁ  ts 
are dose related but higher doses are more likely to provoke 
dangerous hyperkalemia (The RALES Investigators 1996). 
Elderly patients seem to beneﬁ  t from aldosterone antago-
nists to the same extent as younger patients (Pitt et al 1999, 
2003, 2005).
Digoxin
Digoxin has modest inotropic and diuretic properties, 
modulates neuro-endocrine function and slows heart rate and 
atrio-ventricular conduction (Gheorghiade et al 1995; Krum 
et al 1995; Slatton et al 1997). In patients in sinus rhythm, 
digoxin appears to improve symptoms (Packer et al 1993) 
but has no overall effect on mortality when added to an ACE 
inhibitor (The Digitalis Investigation Group 1997). There are 
no randomized data exploring differential effects of digoxin 
in elderly subgroups.
Angiotensin receptor blockers (ARBs)
These agents block the effects of angiotensin II and can be 
used as an alternative or in addition to ACE inhibitors. They 
are likely to be as effective as ACE inhibitors (Granger et al 
2003). For patients who cannot tolerate ACE inhibitors, for 
example due to cough or angio-neurotic edema, ARBs may 
be used as an alternative (Maggioni et al 2002; Granger 
et al 2003). Adding an ARB to the combination of ACE 
inhibitors and β-blockers reduces morbidity and mortality 
in CHF (McMurray et al 2003) despite one study suggesting 
adverse effects (Cohn et al 2001). In post-infarct patients 
with clinical evidence of heart failure, either an ACEi or 
an ARB can be used, but the combination of both increases 
side effects and offers no additional reduction in mortality 
(Pfeffer et al 2003).
The CHARM program was a randomized study comparing 
the ARB, candesartan, with placebo in three different sub-
studies. It enrolled more than 700 over the age of 80 (Granger 
et al 2003; McMurray et al 2003). The mean daily dose of 
candesartan was lower in the elderly, but overall the relative 
reduction in mortality was the same as in younger patients. 
However, since older patients had more events, the number 
needed to treat to “save” a life was lower in the elderly cohort. 
Older patients had more hypotension and renal dysfunction 
than younger patients, but the difference in these side effects 
between the placebo and active therapy groups was not dif-
ferent across age groups.
Adrenergic activity in chronic 
heart failure
In health, the major autonomic inﬂ  uence on the heart at rest 
is the parasympathetic. The circulation is under the control of 
resting sympathetic tone resulting from continuous outﬂ  ow 
from the vasomotor centre in the brain stem. Major inputs to 
the vasomotor centre come from the carotid and aortic baro-
receptors, central cardiopulmonary receptors, chemoreceptors 
and muscle derived receptors (metabo- or ergo- receptors), 
stimulation of which results in sympathetic activation. In 
response to an increase in blood pressure detected by the baro-
receptors, the vasomotor centre reduces constrictor tone and 
increases parasympathetic outﬂ  ow. Central cardiopulmonary 
receptors have a similar effect. When stimulated by stretch, 
they cause a decrease in sympathetic and increase in parasym-
pathetic outﬂ  ow (Mohanty et al 1987; Grassi et al 1988). The 
ergoreceptors are sensitive to work performed by exercising 
skeletal muscle (Iaria et al 1959; Rowell and O’Leary 1990), 
and lead to a withdrawal of parasympathetic tone (Rowell 
and O’Leary 1990) as well as an enhancement of adrenergic 
activity (Rowell and O’Leary 1990; Iellamo et al 1999).
The heart failure syndrome is associated with adrenergic 
overactivity (Leimbach et al 1986; Davis et al 1987), which 
is linked to an adverse prognosis (Cohn et al 1984; Rector 
et al 1987; Kaye et al 1995). The traditional explanation for 
adrenergic activation in heart failure centers on the barore-
ﬂ  exes. The generally adopted concept is that reduced cardiac 
contractility leads to lower blood pressure, and a withdrawal 
of baroreﬂ  ex activity, resulting in a reduction in the inhibi-
tory input to adrenergic control (Mancia et al 1990, 1992). 
The consequent adrenergic activation is the body’s attempt 
to maintain blood pressure by causing vasoconstriction 
(Harris 1987). However, the increased peripheral resistance 
feeds back as an increase in left ventricular afterload, further 
depressing cardiac function. Blood pressure does not rise Clinical Interventions in Aging 2008:3(1) 59
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in response to the vasoconstriction in heart failure, and so 
further adrenergic activation occurs as a consequence of 
withdrawal of the normal baroreﬂ  ex inhibition of sympa-
thetic activity. These changes are seen at an early stage in 
the development of heart failure (Grassi et al 1995a).
In fact, the baroreﬂ  exes are blunted in heart failure 
(Ferguson et al 1984; Ellenbogen et al 1989; Marin-Neto 
et al 1991; Grassi et al 1995b), and it seems likely that 
the baroreﬂ  exes, rather than being the cause of adrenergic 
activation, are down-regulated as a consequence of chronic 
sympathetic overactivity caused by something else.
Enhanced ergoreﬂ  ex activity may lie with the abnormal 
skeletal muscle seen in heart failure patients. Muscle bulk 
(Mancini et al 1992), strength (Buller et al 1991) and endur-
ance (Minotti et al 1992) are reduced; histology is abnormal 
(Lipkin et al 1988; Mancini et al 1989), as is the biochemical 
content of skeletal myocytes (Sullivan et al 1990). Experi-
ments in normal subjects suggest that induced changes in 
muscle metabolism may cause ergoreﬂ  ex activation (Clark 
et al 1995). These ﬁ  ndings form the basis of the “muscle 
hypothesis” (Clark et al 1996) which suggests that many of 
the pathophysiological abnormalities of heart failure result 
from abnormal skeletal muscle with consequent ergoreﬂ  ex 
and adrenergic activation.
Adrenergic antagonists
Mechanisms of beneﬁ  t
The sympathetic nervous system activation in heart failure 
contributes to vasoconstriction, accelerates adverse remodel-
ing, provokes arrhythmias, may be directly toxic to cardiac 
myocytes and can stimulate renin-angiotensin system activa-
tion and hypokalemia (Cleland et al 1996). These effects are 
mediated by beta-1, beta-2 and alpha-1 receptors. Agents that 
block the beta-1 receptor can reduce the effects of sympa-
thetic activation, although agents that block a greater array 
of receptors may be even more effective (Poole-Wilson et al 
2002; Poole-Wilson, Swedberg et al 2003).
Adverse remodeling
Chronic adrenergic stimulation leads to calcium loading of 
the cardiomyocytes and thereby to impaired contractility, 
and cell death (Wynne et al 1996). Not only does adrenergic 
antagonism prevent further deterioration in left ventricular 
dysfunction, but over several months can lead to reduction in 
left ventricular volume and increase in ejection fraction (Hall 
et al 1995; Bristow et al 1996). This effect is likely to underlie 
some of the beneﬁ  t of β-blockers on hospitalization and death 
due to heart failure and is probably due to a combination of 
increased myocardial perfusion (perhaps due to bradycardia 
(Thackray et al 2006)) and reduced afterload.
Prevention of cardiomyocytes apoptosis
Chronic sympathetic activation causes cardiomyocyte 
apoptosis (Communal et al 2003; Goldspink et al 2003) 
which leads to ongoing contractile loss and ﬁ  brosis (Dorn 
2002). Blocking these stimuli reduces apoptosis (Patterson 
et al 2004).
Reduction of arrhythmia
Cardiac adrenergic stimulation leads to an increase in ven-
tricular dysrhythmia (Meredith et al 1991) by shortening the 
action potential thereby increasing the potential for ventricu-
lar dysrythmias. β-blockade lengthens the action potential, 
thereby reducing ventricular ectopy and non-sustained ven-
tricular tachycardia even in patients with severe heart failure 
(Aronson et al 2002).
Renin-angiotensin system activation
Sympathetic activation leads to an increase in the activity of 
the renin-angiotensin system with the consequent vasocon-
striction, sodium and water retention and cardiomyocytes 
apoptosis mediated by angiotensin II and aldosterone. The 
hypokalemia induced by renin-angiotensin system activation 
is pro-arhythmogenic. Renin levels are reduced by carvedilol 
administration (Cohen-Solal et al 2004).
Reduction in ischemia
Ischemic but viable myocardium is not contractile, yet some 
degree of recovery is possible. Hence, in addition to reduc-
ing ongoing cell death as discussed above, by lengthening 
diastole and increasing myocardial perfusion, β-blockers 
might encourage the regeneration of contractile proteins 
within hibernating myocardial cells. This hypothesis has been 
tested in the Christmas study described below (Bellenger 
et al 2004).
Vasodilator effect
Increased peripheral vascular resistance is a feature of chronic 
heart failure. The increased afterload placed on the left ven-
tricle contributes to the adverse remodeling and deterioration 
in ventricular dysfunction and reduction of afterload has long 
been seen as an aim in the treatment of CHF (Franciosa et al 
1977). Peripheral capacitance vessels have both vasodilating 
β2 and constricting α-adrenergic receptors. Cardiac-selective 
β1- adrenergic antagonists have little afterload-reducing effect, 
but non selective β1 and β2 antagonists can cause peripheral 
vasoconstriction. However, α-blockade can have beneﬁ  cial Clinical Interventions in Aging 2008:3(1) 60
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effects on symptoms, left ventricular function and exercise 
tolerance probably through afterload reduction (Awan et al 
1977). Carvedilol is the only non-selective α and β-adrenergic 
antagonist currently used in patients with CHF. Although 
cardio-selective, nebivolol has a vasodilating effect due to 
its action on the L-arginine/nitric oxide pathway.
Beta-blockers in chronic heart failure
β-blockers as therapy for heart failure have been investigated 
in a number of settings. Table 1 summarizes the largest of the 
randomized-placebo controlled trials and one head-to-head 
comparison of β-blockers in heart failure.
Several large studies have examined the use of beta-block-
ers in patients with chronic heart failure. β-blockers seem not 
improve symptoms in the short-term and they may make them 
worse (Macmahon et al 1997). In the long-term however, 
they improve symptoms of breathlessness in many patients 
(Witte et al 2005) and stop them getting worse in many more 
(Packer et al 2002). β-blockers reduce the risk of hospitaliza-
tion, mainly by reducing the risk of worsening heart failure 
(CIBIS investigators 1999; MERIT-HF study group 1999; 
Hjalmarson et al 2000; Packer, Coats et al 2001; Packer et al 
2002), and they also reduce the overall proportion of time that 
the patient spends in hospital (CIBIS-II investigators and com-
mittee 1999; The MERIT-HF study group 1999; Hjalmarson 
et al 2000; Packer, Coats et al 2001; Packer et al 2003). These 
agents may increase average life expectancy by 12–24 months 
(Packer, Bristow et al 1996; MERIT-HF study group 1999; 
Hjalmarson et al 2000; Packer, Coats et al 2001; Packer et al 
2002), in addition to that offered by ACE inhibitor therapy. 
Traditionally ACE inhibitors are the ﬁ  rst-line agents in such 
patients, although β-blockers can be initiated as ﬁ  rst line safely 
in patients with stable symptoms (Willenheimer et al 2005).
The Christmas study demonstrated that the improvement 
in left ventricular function seen with carvedilol was greater in 
those patients with evidence of hibernating myocardium than 
in those with no reversibility of perfusion defects (Bellenger 
et al 2004). Thus, by prolonging diastole and improving per-
fusion, carvedilol might lead to the recovery of hibernating 
cells (those with the capacity to recover contractile function). 
However, since ischemia/reperfusion is a major stimulus to 
apoptosis, the reduction of ischemia might lead to reduced 
programmed cell death and a prevention of further deteriora-
tion in cardiac function.
Sudden death is a common event in patients with CHF 
(Poole-Wilson, Uretsky et al 2003), with an annualized 
incidence up to 11% in those with three of higher brain 
natriuretic peptide (BNP) levels, poorer left ventricular 
function (EF  30% or left ventricular end diastolic 
diameter  60mm), diabetes or non-sustained ventricular 
tachycardia (Watanabe et al 2006). By lengthening the 
action potential, reducing the incidence of ventricular ectopy, 
reducing ischemia and improving left ventricular function, 
β-blockers lead to a signiﬁ  cant reduction in sudden death 
(Brodine et al 2005).
No study has speciﬁ  cally examined the use of β-blockers 
in elderly patients with chronic heart failure speciﬁ  cally due 
to left ventricular systolic dysfunction. Nevertheless, most 
of the trials have included older patients (Table 1) such that 
more patients with chronic heart failure aged  65 years have 
been randomized into studies of β-blockers than other agents 
used for heart failure therapy. In the early US carvedilol trials 
in which half of the enrolled patients were elderly (deﬁ  ned 
as  59 years!), there was no difference in the risk reduction 
with carvedilol between older and younger patients. In the 
MERIT study with metoprolol, patients older than the median 
(69.4 years) had the same mortality beneﬁ  t as those below the 
median age (Hjalmarson et al 2000; Deedwania et al 2004). 
CIBIS II (using bisoprolol) enrolled 539 patients over 71 years, 
in whom the risk reduction of death or hospitalization over the 
duration of the study period (16 months) was similar to that seen 
in the younger patient group. Although the BEST study did not 
conﬁ  rm the mortality advantage of bucindolol over placebo 
(Beta-Blocker Evaluation of Survival Trial Investigators 
2001), there was once again no difference in outcomes between 
elderly ( 65 years) and younger patients.
Observational studies in older patients ( 65 years) have also 
demonstrated reductions in mortality and hospital admissions 
(Sin and McAlister 2002) and increases in left ventricular 
ejection fraction (Krum, Hill et al 2006) similar to those seen in 
the subgroup analyses. There seems to be no difference between 
older patients and very elderly patients ( 80 years) in terms 
of increase in LVEF (Krum, Hill et al 2006).
Finally a meta-analysis, combining the effects of all 
of the major β-blocker studies and using data from 12,729 
patients (4,617 elderly) conﬁ  rms that older patients have the 
same beneﬁ  t in all outcomes as younger patients (Figure 2) 
(Dulin BR et al 2005).
Beta-blockers in post-infarct heart failure
β-blockers reduce mortality after myocardial infarction, 
predominantly by reducing sudden death and the risk of 
recurrent infarction (Freemantle et al 1999; Houghton et al 
2000). The only placebo-controlled randomized study to 
examine the beneﬁ  ts of β-blockade in patients with post-
myocardial infarction heart failure demonstrated signiﬁ  cant Clinical Interventions in Aging 2008:3(1) 61
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reductions in mortality and readmission with carvedilol 
(Dargie 2001). This study included elderly patients, but no 
subgroup analysis has been published. Carvedilol therapy 
was associated with increased ejection fraction and reduced 
left ventricular volumes at follow-up (Doughty et al 2004) 
and reduced atrial and ventricular arrhythmias, and caused a 
reduction in sudden death (McMurray et al 2005).
Beta-blockers in asymptomatic left 
ventricular dysfunction
β-blockers in combination with ACE inhibitors can reduce 
the progression of heart failure in patients with asymptomatic 
left ventricular dysfunction (Remme et al 2004), or mild 
heart failure (Colucci et al 1996). Furthermore, in mild heart 
failure, the prescription of a β-blocker as ﬁ  rst line does not 
have an adverse effect and is well tolerated (Komadja et al 
2004). There are no published data examining the effect of 
age in this group of patients.
Beta-blockers in severe chronic 
heart failure
There are two placebo-controlled studies in patients with 
severe heart failure, both with carvedilol. The Precise trial 
enrolled patients with severe symptoms of heart failure 
(mainly NYHA class III) and demonstrated improvements in 
symptoms, NYHA status and six-minute walk test distance, 
in those treated with carvedilol, irrespective of the etiology of 
the heart failure (Packer, Colucci et al 1996). No age-based 
subgroup analysis has been published. The mortality at six 
months in the placebo group was 8% at 6 months conﬁ  rming 
that these patients had severe heart failure.
The only study selectively to recruit patients with 
decompensated heart failure was COPERNICUS (Packer, 
Coats et al 2001; Packer et al 2003). Patients in this study 
could be on intravenous diuretics, but not positive inotropic 
agents. However, that they were sick is shown by a 42% 
one year hospitalization or death rate in the placebo group. 
The beneﬁ  ts were striking even in this population of very 
sick patients (Figure 3) and were seen within the first 
month from randomization (Krum et al 2003). The greatest 
reduction in mortality was noted in those patients with a 
recent admission for decompensation of heart failure or very 
poor left ventricular systolic function (Krum et al 2003). The 
beneﬁ  t was seen despite the high level of use of other disease 
modifying drugs (Krum, Mohacsi et al 2006). There were no 
differences in the beneﬁ  t from carvedilol between patients 
under 65 years and those over 65 years.
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Figure 2 Box plot of beta-blocker versus placebo for older patients in each of the major randomized studies of beta-blockade in chronic heart failure. Point estimates and 
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Heart failure and atrial ﬁ  brillation
Atrial ﬁ  brillation is more frequent in elderly patients with 
chronic heart failure (Cleland et al 2002). It is an important 
marker for worse outcome (Middlekauff et al 1991; Dries 
et al 1998; Swedberg et al 2005). β-blocker therapy leads to 
similar reductions in mortality and morbidity in patients with 
atrial ﬁ  brillation as in those with sinus rhythm (Joglar et al 
2001; Fung et al 2002). Use of carvedilol in elderly patients 
with atrial ﬁ  brillation is as safe and as well-tolerated as in 
patients with sinus rhythm with similar reduction in hospitali-
sations (Ciofﬁ   et al 2006) and improvement in left ventricular 
function (Opasich et al 2005).
Patients with heart failure and atrial ﬁ  brillation often have 
poor rate control during exercise. Digoxin has little effect on 
atrio-ventricular conduction during exercise. The addition of 
carvedilol in such patients to digoxin leads to superior rate 
control to either alone (Khand et al 2003).
Heart failure with preserved left 
ventricular systolic function
Until recently, there had been little published data on the 
effects of β-blockade speciﬁ  cally in elderly patients with 
chronic heart failure. Older patients may represent a slightly 
different population of patients from those commonly 
recruited to clinical trials. A greater proportion of older 
patients with heart failure have apparently preserved left 
ventricular systolic function; they are more likely to have 
atrial ﬁ  brillation; they are more likely to be female; and they 
are much more likely to have co-morbidity.
The ﬁ  rst randomized study to suggest a potential beneﬁ  t 
of β-blockers in a population of 158 older patients (mean age 
81 years) with NYHA functional class II or III disease, prior 
myocardial infarction, and heart failure with left ventricular 
ejection fractions of 40% or higher used propranolol. All 
patients were treated with diuretics and ACE inhibitors at 
baseline and mean ejection fraction was 56%. At the end of 
the follow-up period, the two end-points of total mortality 
(RR 0.65) and mortality plus non-fatal myocardial infarction 
(RR 0.63) were signiﬁ  cantly reduced in patients taking the 
β-blocker (Aronow et al 1997).
The only large randomized placebo-controlled study 
of β-blockers in elderly patients with chronic heart failure 
included 2128 patients with clinical evidence of heart fail-
ure, or impaired left ventricular systolic function. Nebivolol 
(mean dose 7.7 mg daily) treatment lead to reductions in 
the primary composite endpoint of all cause mortality or 
cardiovascular hospitalization (31% v 35%; p = 0.039) but no 
reduction in all cause mortality as a result of a very low event 
rate (Figures 4a and 4b) (Flather et al 2005). In patients with 
impaired ventricular function, (LVEF   35%) (n = 684) there 
was a signiﬁ  cant reduction in all-cause mortality (RR 0.62). 
In this group, LV ejection fraction increased and LV volume 
decreased (Ghio et al 2006). There was no change in LV 
variables in those with higher ejection fraction at baseline. 
There were no differences in the beneﬁ  t of nebivolol between 
patients aged 75 and 85 and patients older than 85 years.
Which beta-blocker?
There are important differences between β-blockers. Sym-
pathomimetic agents with partial agonist activity, such as 
xamoterol, initially thought to be of potential beneﬁ  t on 
exercise capacity in patients with left ventricular dysfunction 
following myocardial infarction (Persson et al 1995), seem to 
confer less beneﬁ  t on long term mortality reduction than those 
without intrinsic sympathomimetic activity. Xamoterol, in fact, 
seems harmful to left ventricular function (Persson et al 1996), 
and its use is associated with a worse outcome than placebo 
(The Xamoterol in Severe Heart Failure Study Group 1990). 
Similarly, bucindolol, a partial agonist at beta-1 receptors 
(Andreka et al 2002), showed no overall beneﬁ  t on mortality 
in patients with chronic heart failure in the BEST study (Beta-
blocker Evaluation of Survival Trial Investigators 2001).
Clinical trial evidence of beneﬁ  t is limited to agents 
without partial agonist or sympathomimetic properties 
(carvedilol, bisoprolol, metoprolol, and nebivolol).
Figure 3 Kaplan–Meier analysis of time to death in the placebo group and the 
carvedilol group. The 35 percent lower risk in the carvedilol group was signiﬁ  cant: 
p = 0.00013 (unadjusted) and p = 0.0014 (adjusted). (Reprinted from Packer M et al 
[106] with permission).Clinical Interventions in Aging 2008:3(1) 63
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Carvedilol has the most widespread effects on adrenergic 
receptors, blocking beta-1, beta-2 and alpha-1 receptors. In 
addition, it has anti-oxidant effects. The suggestion that non-
selective blockade might be of additional beneﬁ  t compared 
with β1 selective antagonism using metoprolol was tested in the 
COMET study (Poole-Wilson, Swedberg et al 2003), which 
randomized 3029 patients to either carvedilol or twice-daily 
short-acting metoprolol at doses used in clinical practice which 
for metoprolol were lower than those used in MERIT (MERIT-
HF Study Group 1999). The average age of the randomized 
patients was 62 (11) years. Patients randomized to carvedilol 
had a 16% lower mortality than those taking metoprolol despite 
similar reductions in heart rate (Figure 5). This reduction 
was exactly the same for older patients ( 65 years) as for 
the younger patients (Poole-Wilson, Swedberg et al 2003). 
Furthermore, patients with left ventricular dysfunction taking 
carvedilol might have a greater increase in ejection fraction 
(Packer, Antonopoulos et al 2001), a less new-onset diabetes 
mellitus (Torp-Pedersen et al 2007), and fewer vascular events 
(Remme et al 2007), than those taking metoprolol, along with 
reduced hospital admissions for all age groups, including 
elderly patients (Poole-Wilson, Swedberg et al 2003; Cleland 
Charlesworth, et al 2006).
Nebivolol has some vasodilating properties, but despite 
a reduction in mortality in the subgroup of patients with 
signiﬁ  cant left ventricular dysfunction (LVEF  35%), the 
SENIORs study did not show an overall mortality reduction 
in elderly patients with chronic heart failure (Flather et al 
2005). It would be useful to see nebivolol agent tested against 
another β-blocker. Therefore, despite the controversy created 
by the COMET study, this remains the only head-to-head 
trial of beta-blockers in patients with chronic heart failure, 
and suggests that non-selective adrenergic blockade might 
be the better option.
Which dose?
Little is known about which dose of β-blocker is most 
effective. Much depends on how well tolerated they are by 
patients. Older patients tolerate higher doses less well than 
younger patients (Krum et al 2000). Lower doses can, how-
ever, lead to an increase in left ventricular ejection fraction 
and reduction in hospitalisation (Rochon et al 2000; Ciofﬁ   
et al 2003). Nevertheless, as with studies in younger popula-
tions, higher doses of β-blocker are associated with a greater 
reduction in mortality (Simon et al 2003; Tandon et al 2004) 
even in very elderly patients (Krum, Hill et al 2006). It is 
important, though, to bear in mind that intolerance to higher 
doses might identify a sicker cohort of patients who have an 
intrinsically worse outcome. The only study to look at the 
subject of dose closely, compared the effects of three doses 
of carvedilol (6.25 mg, 12.5 mg, and 25 mg each twice a day) 
and placebo in 345 CHF patients on mortality, exercise capac-
ity (6-minute walk test), hospitalizations and left ventricular 
ejection fraction (Bristow et al 1996). There was no effect of 
the β-blocker on walk distance and there were fewer hospi-
talization with carvedilol at any dose. However, there was a 
dose-related increase in left ventricular ejection fraction and 
reduction in mortality during the six-month follow-up period. 
Thus, even in elderly patients, it seems prudent to increase 
the β-blocker to the maximally tolerated dose.
Side effects and tolerability
Side effects include bradycardia, hypotension, temporary 
worsening of heart failure and fatigue. β-blockers are 
Figure 4 Time to (a) ﬁ  rst occurrence of events (all cause death or hospital admission 
for a cardiovascular reason – primary endpoint) and (b) all cause death in patients 
randomized to nebivolol or placebo. (Reprinted from Flather MD et al [137] with 
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probably not as well tolerated as ACE inhibitors (Cleland, 
McGowan et al 1998; Cleland, Gemmell et al 1999). Despite 
this, most symptoms do not lead to withdrawal of the medica-
tion. For example, in the US Carvedilol heart failure study 
dizziness was seen in 33% of those taking carvedilol and 
20% in those taking placebo but was not associated with 
withdrawal of study medication (Packer, Bristow et al 1996). 
In the same study, worsening of CHF was the most common 
reason to stop therapy but was more common in those taking 
placebo (Packer, Bristow et al 1996). Interestingly, not all 
studies have conﬁ  rmed that β-blockers are a major cause of 
fatigue (Ko et al 2002). In the Copernicus study, performed 
in patients with severe heart failure, many requiring intra-
venous diuretics, patients in the carvedilol group were more 
likely to require a dose reduction than those randomized to 
placebo, (38.3% v 33.2%; p   0.01), but were less likely 
to have the drug withdrawn (12.6% v 15.9%, respectively, 
p   0.03). In addition, even in these patients with severe 
heart failure, 74% tolerated carvedilol at the target dose. In 
fact, those with lower systolic blood pressure had a greater 
absolute beneﬁ  t from the β-blocker (since they had a greater 
absolute risk) than those with higher systolic blood pressure 
(Rouleau et al 2004).
Few studies have speciﬁ  cally addressed tolerability in the 
elderly. One observational study found that the very elderly 
( 80 years) tolerated carvedilol less well than their younger 
peers (70–79 years) (Krum, Hill et al 2006). Nevertheless, in 
this very elderly group, more than 76% tolerated doses higher 
than the starting dose of carvedilol. Once the patients were 
stabilized, discontinuation of the higher dose of carvedilol 
over the follow-up period was not different between the 
groups. Older patients ( 70 years) tolerate carvedilol as 
frequently and to the same doses as patients under 70 years 
(Nul et al 2005; Lawless et al 2005). Carvedilol seems not 
to have adverse effects on cognitive function or functional 
capacity in elderly patients (Leonetti-Luparini et al 1999).
Heart rate and blood pressure reductions for equivalent 
doses are the same in older as in younger patients despite 
the fact that older patients are more likely to have a longer 
duration of CHF, more likely to have ischemic heart disease 
as the etiology of their CHF, higher NYHA scores, higher 
noradrenaline levels and overall higher placebo group mor-
tality than their younger counterparts (Aranda et al 2002). 
Outpatient initiation and uptitration of carvedilol appears 
to be safe, even in an elderly population (Rickli et al 2004; 
Opasich et al 2006).
Co-morbidities and beta-blocker 
therapy
Elderly patients are more likely to have other chronic condi-
tions in addition to their CHF. This has potential implications 
for their management. The co-morbidities do not reduce the 
beneﬁ  ts patients gain from β-blockers, however, and may in 
some cases have an additional beneﬁ  cial effect. β-blockers 
are often reported anecdotally to worsen diabetic control 
and can blunt the symptoms of hypoglycemia. However, 
carvedilol is as well tolerated in non-diabetics as in diabet-
ics (Nodari et al 2003), leads to a decrease in insulin resis-
tance (Ferrua et al 2005), and no increase of glycosylated 
hemoglobin (HbA1c). Metoprolol, on the other hand, had 
no effect on insulin resistance and was associated with an 
increase in HbA1c level (Kveiborg et al 2006; Bakris et al 
2004). Diabetics with heart failure have a similar reduction 
in mortality with carvedilol as their non-diabetic counterparts 
(Bell et al 2006).
Peripheral vascular disease is also often thought to be a 
contraindication to β-blockade; however, worsening of clau-
dication has not been reported as an adverse event in trials of 
systolic heart failure. Furthermore, studies of β-blockers in 
patients with known peripheral vascular disease have dem-
onstrated that neither metoprolol nor propranolol worsened 
claudication distance or peripheral perfusion (Hiatt et al 
1985). Carvedilol has the advantage that it might have some 
peripheral vasodilating properties, although it is not known if 
these persist long term (Kubo et al 2001), which might reduce 
the potential for worsening of claudicant symptoms.
Chronic airways disease is particularly common in patients 
with chronic heart failure, and the prevalence increases with 
age. The fear of inducing a deterioration in lung function is a 
factor in the under-prescribing of β-blockers in CHF patients. 
Figure 5 Kaplan-Meier estimates of all-cause mortality for carvedilol and metopro-
lol. The hazard ratio was 0.83 (95% CI 0.74–0.93, p = 0.0017) in favor of carvedilol. 
(Reprinted from Poole-Wilson et al [144] with permission).Clinical Interventions in Aging 2008:3(1) 65
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However, most patients with chronic obstructive pulmonary 
disease (COPD) do not have reactive bronchospasm (Hunt 
et al 2001), and even if there were a reactive component, 
the alpha-adrenergic blockade of carvedilol might offset 
some of the bronchoconstriction induced by β-blockade 
(Sirak et al 2004). In any case, β-blockers are well tolerated 
in CHF (Kotylar et al 2002; Shelton et al 2006) and post-
infarct (Chen et al 2001) patients with COPD, with little 
change in pulmonary function tests (Sirak et al 2004; Witte 
and Clark 2005).
Practical issues
Patients with preserved blood pressure or hypertensive 
patients will generally tolerate initiation of β-blocker and 
uptitration well. We often prescribe both the starting dose 
and the ﬁ  rst titration dose on the same prescription in such 
patients, allowing a review at four rather than two weeks. In 
patients in whom there is a concern about hypotension, the 
loop diuretic dose should be reduced, or even omitted, on the 
ﬁ  rst day. Alternatively, a slight reduction in the ACE inhibitor 
or angiotensin antagonist will allow safe uptitration.
Concerns over the consequences of the hemodynamic 
changes are frequently not realized even in those with sys-
tolic blood pressure around 100 mmHg and although early 
symptoms of postural hypotension often recur at each titration 
stage, they often settle once the patient is established on the 
increased dose. Finally, in patients where an increase in only 
one agent (β-blocker or ACE inhibitor) seems feasible, one 
should keep in mind that the remodeling effects of β-blockers 
are dose dependant, and a policy of increasing the β-blocker 
over the ACE inhibitor leads to a better response in terms of 
LV function (Sliwa et al 2004).
If a patient is admitted to hospital with an episode of 
decompensation of their heart failure, β-blocker therapy is 
commonly stopped in the short term. Once patients have 
stabilized, we recommend that the β-blocker is restarted 
prior to discharge, since this improves long term uptake 
(Gattis et al 2004).
Conclusions
One of the great joys for physicians working with patients 
with chronic heart failure is that our practice is strongly 
informed by compelling evidence from clinical trials, and 
that evidence demonstrates that we can now have a profound 
impact on the quantity and quality of life of our patients. 
There are compelling data supporting the use of β-blockers 
in patients over 65 years. More patients have been enrolled 
in clinical trials of β-blockers than in studies of other agents, 
and no important differences in outcomes between younger 
and older patients have been found. Contrary to popular 
belief, β-blockers are well tolerated, even in the presence of 
co-morbidities, and can be safely initiated in older patients both 
in the outpatient setting and before discharge from hospital 
following an acute exacerbation of heart failure. Although 
care is needed, physicians treating older patients with chronic 
heart failure need to be conﬁ  dent in initiating and up-titrating 
β-blockers in this group of high risk individuals.
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